Nedd9在宫颈癌组织中的表达及临床意义

Clinical value on the Nedd9 expression in the cervical cancer pathological tissues

目的本研究的目的旨在评估神经前体发育下调9细胞(NEDD9)在宫颈癌组织中的表达情况及其与临床病理特征之间的关系。NEDD9的表达在许多人类恶性肿瘤中都被检测到,并与疾病的进展和不良预后相关。方法通过RT-PCR法分析各组组织中NEDD9的表达量。计算各组表达量采用相对定量法,检测的组织分类为正常宫颈组10/49,宫颈上皮内瘤变组13/49、癌症组26/49。结果 NEDD9的表达量随着癌症的进展明显上升,运用统计学软件和方法比较差异性表达是否有统计学意义,结果显示,宫颈上皮内瘤变组与正常组统计学比较有意义(P<0.05),癌症组与宫颈上皮内瘤变组和正常组比较均具有统计学意义(P<0.05)。分析癌症组与某些临床特征之间的关系显示,NEDD9与肿瘤细胞分化程度有关(P<0.05),与患者年龄、临床分期无关(P>0.05)。结论 NEDD9与宫颈癌的发生发展有一定的关系,我们的研究暗示NEDD9可以作为预测指标和潜在分子治疗靶点用于高表达NEDD9的宫颈癌患者。

Objective：The purpose of this study was to evaluate the development of neural precursor cells down 9（NEDD9）relations in between cervical cancer and its expression with clinicopathological features. NEDD9 expression in many human cancers have been detected and associated with disease progression and poor prognosis. Methods：Expression of NEDD9 in each group was detected by real-time fluorescence quantitative RT-PCR method. The expression of each group is calculated using the relative quantification method,detection of tissue in normal cervical tissue classification group 10/49,cervical intraepithelial neoplasia group 13/49、cancer group26/49.Results：The results of the expression of NEDD9 in each group significantly increased with the progress of the cancer. Using of statistical software and comparative whether the expression was statistically significant differently. The results show,cervical intraepithelial neoplasia group and the normal group compared statistically significant（P〈0.05）,the cancer group and cervical intraepithelial neoplasia group and the normal group were statistically significant（P〈0.05）. Relationship analysis between groups with cancer and certain clinical characteristics showed that the expressing of NEDD9 relevant with the degree of differentiation of tumor cells（P〈0.05）,but unrelated with age,clinical stage（P〉0.05）. Conclusions：NEDD9 and the development of cervical cancer have a certain relationship,our research suggests that NEDD9 can be used as predictors and potential molecular targets for the treatment of cervical cancer patients with high expression of NEDD9.